| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | J M Domagala | |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | quinolones | Q426549 |
| P304 | page(s) | 685-706 | |
| P577 | publication date | 1994-04-01 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | Structure-activity and structure-side-effect relationships for the quinolone antibacterials | |
| P478 | volume | 33 |
| Q37579919 | 10 years' experience with the pneumococcal quinolone moxifloxacin |
| Q37204002 | A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone |
| Q44424794 | A Novel Antibacterial 8-Chloroquinolone with a Distorted Orientation of the N1-(5-Amino-2,4-difluorophenyl) Group |
| Q28215446 | A critical review of the fluoroquinolones: focus on respiratory infections |
| Q28369049 | A new approach for early assessment of the epileptogenic potential of quinolones |
| Q37291866 | A novel two-step hierarchical quantitative structure-activity relationship modeling work flow for predicting acute toxicity of chemicals in rodents |
| Q34625911 | A review of antibiotics in dermatology |
| Q34248416 | A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections |
| Q46404982 | Abatement by naringin of lomefloxacin-induced genomic instability in mice |
| Q34304883 | Absorption Interactions With Fluoroquinolones 1995 Update |
| Q31935738 | Advances in DNA gyrase inhibitors |
| Q37880021 | Advances in the macrolides and quinolones |
| Q92258114 | Adverse Effects of Fluoroquinolones: A Retrospective Cohort Study in a South Indian Tertiary Healthcare Facility |
| Q30762340 | Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions. |
| Q53058971 | An integrated approach for detection and characterization of the trace impurities in levofloxacin using liquid chromatography-tandem mass spectrometry. |
| Q73482123 | Analyses of cutaneous fluoroquinolones photoreactivity using the integrated model for the differentiation of skin reactions |
| Q55034478 | Anaphylactoid reaction to levofloxacin. |
| Q28344751 | Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques |
| Q33983352 | Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent |
| Q35085323 | Antibiotic safety assessment |
| Q28255152 | Antimicrobial safety: focus on fluoroquinolones |
| Q50120381 | Antimutagenesis of beta-carotene to mutations induced by quinolone on Salmonella typhimurium |
| Q38012651 | Antituberculosis drug research: a critical overview. |
| Q52534357 | Apoptotic photoreceptor cell death induced by quinolone phototoxicity in mice. |
| Q34104362 | Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations |
| Q35003633 | Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor |
| Q53149120 | Biodegradation potential of ofloxacin and its resulting transformation products during photolytic and photocatalytic treatment. |
| Q46458071 | Bone-targeting of quinolones conjugated with an acidic oligopeptide |
| Q39785242 | Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds. |
| Q39311454 | Chiral separation of quinolones by liquid chromatography and capillary electrophoresis |
| Q40939775 | Classification and structure-activity relationships of fluoroquinolones |
| Q33982914 | Clinafloxacin pharmacokinetics in subjects with various degrees of renal function |
| Q33981431 | Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections |
| Q34030783 | Clinical pharmacology of gatifloxacin, a new fluoroquinolone |
| Q34774058 | Clinical role of protein binding of quinolones |
| Q33985235 | Clinical use of fluoroquinolones in children |
| Q34130062 | Clinical use of the fluoroquinolones |
| Q38254554 | Combined use of in vitro phototoxic assessments and cassette dosing pharmacokinetic study for phototoxicity characterization of fluoroquinolones. |
| Q44281555 | Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group |
| Q43828252 | Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and beta-lactams against gram-positive bacteria |
| Q35136236 | Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections |
| Q33319312 | Comparative study of the antimutagenic properties of vitamins C and E against mutation induced by norfloxacin |
| Q28146268 | Comparative tolerability of the newer fluoroquinolone antibacterials |
| Q46699483 | Comparison of rifampicin and moxifloxacin efficacy in an experimental model of animal brucellosis |
| Q34528916 | Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus |
| Q43294249 | Convulsant activity and pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of gemifloxacin in rats |
| Q40902870 | DNA gyrase as a drug target |
| Q39481224 | Degradation of ciprofloxacin by basidiomycetes and identification of metabolites generated by the brown rot fungus Gloeophyllum striatum |
| Q43345765 | Degradation of ciprofloxacin by cryptomelane-type manganese(III/IV) oxides |
| Q28254007 | Degradation of the fluoroquinolone enrofloxacin by the brown rot fungus Gloeophyllum striatum: identification of metabolites |
| Q44416638 | Design, Synthesis and Biological Evaluation of Oxazolidinone–Quinolone Hybrids |
| Q34020997 | Detection and prevention of ocular phototoxicity of ciprofloxacin and other fluoroquinolone antibiotics |
| Q64104924 | Determination of two fluoroquinolones and their combinations with hyaluronan effect in canine cartilage explants |
| Q74028744 | Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group |
| Q35374935 | Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin |
| Q53541410 | Dissemination of bacterial fluoroquinolone resistance in two multidrug-resistant enterobacteriaceae. |
| Q40888785 | Drug administration in chronic liver disease |
| Q33982922 | Drug interactions with clinafloxacin |
| Q82691208 | Drug prescribing in children in a North Indian referral hospital |
| Q34142238 | Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone |
| Q45158524 | Early pathophysiologic feature of arthropathy in juvenile dogs induced by ofloxacin, a quinolone antimicrobial agent |
| Q41945652 | Effect of hydroxyl groups and rigid structure in 1,4-cyclohexanediol on percutaneous absorption of metronidazole |
| Q33789233 | Effects of liver disease on pharmacokinetics. An update |
| Q40646300 | Effects of lomefloxacin and norfloxacin on pancreatic beta-cell ATP-sensitive K(+) channels |
| Q33866649 | Effects of novel 6-desfluoroquinolones and classic quinolones on pentylenetetrazole-induced seizures in mice |
| Q42785258 | Effects of substituents on the NMR features of basic bicyclic ring systems of fluoroquinolone antibiotics and the relationships between NMR chemical shifts, molecular descriptors and drug-likeness parameters |
| Q33739099 | Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review |
| Q39469535 | Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis |
| Q43193286 | Efficient Synthesis of the 2-amino-6-chloro-4-cyclopropyl-7-fluoro-5-methoxy-pyrido[1,2-c]pyrimidine-1,3-dione core ring system |
| Q43214932 | Evaluation of Surrogate Disk Tests for Detection of Ciprofloxacin and Levofloxacin Resistance in Clinical Isolates of Salmonella enterica |
| Q39126769 | Evaluation of quinolone derivatives for antitrypanosomal activity |
| Q33544588 | Expanded activity and utility of the new fluoroquinolones: a review |
| Q34408447 | Fluoroquinolone adverse effects and drug interactions |
| Q46862305 | Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase |
| Q73829736 | Fluoroquinolones |
| Q36082020 | Fluoroquinolones and tendon disorders |
| Q34958317 | Fluoroquinolones for the treatment of outpatient community-acquired pneumonia |
| Q35086805 | Fluoroquinolones in the elderly: safety considerations |
| Q26746197 | Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections |
| Q43946478 | Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics |
| Q44616842 | Gatifloxacin, Gemifloxacin, and Moxifloxacin: The Role of 3 Newer Fluoroquinolones |
| Q31975922 | Gatifloxacin, an advanced 8-methoxy fluoroquinolone |
| Q37867123 | Gemifloxacin: a new fluoroquinolone |
| Q35798789 | Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections |
| Q35964735 | Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections |
| Q43352551 | Genotoxicity of quinolone antibiotics in chlorination disinfection treatment: formation and QSAR simulation |
| Q33544591 | Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance |
| Q34558942 | Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety |
| Q36126509 | Guide to selection of fluoroquinolones in patients with lower respiratory tract infections |
| Q43269717 | High Dose Ofloxacin-induced Bimodal Hallucinations in a 4 Years Old Child |
| Q54172025 | In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria. |
| Q42687338 | In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis |
| Q35125320 | In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone |
| Q44008994 | In vitro photochemical clastogenicity of quinolone antibacterial agents studied by a chromosomal aberration test with light irradiation |
| Q42808529 | In vitro phototoxic properties of new 6-desfluoro and 6-fluoro-8-methylquinolones |
| Q40551747 | In vitro studies on DNA-photosensitization by different drug stereoisomers. |
| Q44151068 | In vivo photochemical micronucleus induction due to certain quinolone antimicrobial agents in the skin of hairless mice |
| Q35119128 | In vivo therapeutic efficacies of PD 138312 and PD 140248, two novel fluoronaphthyridines with outstanding gram-positive potency |
| Q44318852 | Inhibition by fluoroquinolones of K(+) currents in rat dissociated hippocampal neurons |
| Q33614494 | Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance |
| Q41231139 | Interrelationship of photocarcinogenicity, photomutagenicity and phototoxicity |
| Q46897790 | Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NONMEM. |
| Q36670872 | Levofloxacin for the treatment of community-acquired pneumonia |
| Q38101380 | Levofloxacin for the treatment of pyelonephritis |
| Q39980085 | Levofloxacin-induced Achilles tendinitis in a young adult in the absence of predisposing conditions |
| Q43890979 | Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract |
| Q33980991 | Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions |
| Q77744274 | Methyloxime-substituted aminopyrrolidine: a new surrogate for 7-basic group of quinolone |
| Q35031124 | Microbiology of newer fluoroquinolones: focus on respiratory pathogens |
| Q34557847 | Mirtazapine therapy for dysgeusia in an elderly patient |
| Q53479485 | Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel. |
| Q35846371 | Moxifloxacin Induced Seizures -A Case Report |
| Q33871466 | Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics |
| Q28379303 | N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies |
| Q37150326 | New drugs and vaccines for drug-resistant Mycobacterium tuberculosis infections |
| Q36489661 | New findings on the structure-phototoxicity relationship and photostability of fluoroquinolones with various substituents at position 1. |
| Q60395359 | Novel 5-amino-6-methylquinolone antibacterials: A new class of non-6-fluoroquinolones |
| Q36924311 | Ocular toxicity of fluoroquinolones |
| Q36865487 | Ofloxacin-induced hallucinations. |
| Q45080632 | Optical control of antibacterial activity |
| Q62624147 | Optimization of the electrochemical degradation process of the antibiotic ciprofloxacin using a double-sided β-PbO2 anode in a flow reactor: kinetics, identification of oxidation intermediates and toxicity evaluation |
| Q40960891 | Past, present, and future of antimicrobial agents |
| Q39471040 | Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of fluoroquinolones in rats |
| Q33856763 | Pharmacokinetics of gatifloxacin in infants and children |
| Q37811606 | Pharmacological and Pharmacoeconomic Considerations |
| Q42142495 | Phosphine-Initiated General-Base-Catalyzed Quinolone Synthesis |
| Q35620896 | Photochemical genotoxicity: principles and test methods. Report of a GUM task force. |
| Q77571944 | Photocleavage of DNA by the fluoroquinolone antibacterials |
| Q33760893 | Possible intermolecular interaction between quinolones and biphenylacetic acid inhibits gamma-aminobutyric acid receptor sites |
| Q33717059 | Potential interactions of the extended-spectrum fluoroquinolones with the CNS. |
| Q28344748 | Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening |
| Q34564526 | Prulifloxacin: a new antibacterial fluoroquinolone |
| Q34634216 | QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications |
| Q35771493 | QT prolongation with antimicrobial agents: understanding the significance |
| Q51713941 | Quantitative structure-activity relationship study of antitubercular fluoroquinolones. |
| Q34140894 | Quinolone Resistance: Older Concepts and Newer Developments |
| Q41107832 | Quinolone antibiotic photodynamic production of 8-oxo-7, 8-dihydro-2'-deoxyguanosine in cultured liver epithelial cells |
| Q91709476 | Quinolone antibiotics |
| Q34347885 | Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity |
| Q77331346 | Quinolone photoallergy: photosensitivity dermatitis induced by systemic administration of photohaptenic drugs |
| Q35126142 | Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. |
| Q38357316 | Quinolone-DNA interaction: sequence-dependent binding to single-stranded DNA reflects the interaction within the gyrase-DNA complex |
| Q33584190 | Real-time visualization of photochemically induced fluorescence of 8-halogenated quinolones: lomefloxacin, clinafloxacin and Bay3118 in live human HaCaT keratinocytes |
| Q38591662 | Review of Properties and Analytical Methods for the Determination of Norfloxacin. |
| Q37577369 | Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections |
| Q34186776 | Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes |
| Q46479708 | Roles of singlet oxygen and dissolved organic matter in self-sensitized photo-oxidation of antibiotic norfloxacin under sunlight irradiation. |
| Q57822396 | Safety of Delafloxacin: Focus on Adverse Events of Special Interest |
| Q36170467 | Safety of fluoroquinolones: An update |
| Q33420394 | Safety profile of sparfloxacin, a new fluoroquinolone antibiotic |
| Q34110521 | Safety profile of the fluoroquinolones: focus on levofloxacin |
| Q39478563 | Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756. |
| Q24672818 | Selective antagonism of the GABA(A) receptor by ciprofloxacin and biphenylacetic acid |
| Q33220958 | Selective entrapment of the cationic form of norfloxacin within anionic sodium dodecyl sulfate micelles at physiological pH and its effect on the drug photodecomposition. |
| Q45013070 | Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy |
| Q91636295 | Sonochemical degradation of antibiotics from representative classes-Considerations on structural effects, initial transformation products, antimicrobial activity and matrix |
| Q83180908 | Spectral-luminescent properties and molecular orbital treatment of some mono- and difluoroquinolones |
| Q28379263 | Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position |
| Q52841800 | Sulfate radical-based oxidation of fluoroquinolone antibiotics: Kinetics, mechanisms and effects of natural water matrices. |
| Q35114831 | Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones |
| Q39781930 | Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). |
| Q38736634 | Synthesis and Evaluation of Antimicrobial Activity of [R₄W₄K]-Levofloxacin and [R₄W₄K]-Levofloxacin-Q Conjugates. |
| Q54110404 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| Q37253878 | Synthesis and antibacterial activity of novel levofloxacin derivatives containing a substituted thienylethyl moiety |
| Q44489591 | Synthesis and biological testing of non-fluorinated analogues of levofloxacin |
| Q42823558 | Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones |
| Q83729021 | Synthesis and in vitro antibacterial activity of 7-(3-amino-6,7-dihydro-2-methyl-2H-pyrazolo[4,3-c] pyridin-5(4H)-yl)fluoroquinolone derivatives |
| Q42910163 | Synthesis and in vitro antibacterial activity of fluoroquinolone derivatives containing 3-(N′-alkoxycarbamimidoyl)-4-(alkoxyimino) pyrrolidines |
| Q42953448 | Synthesis and in vitro antibacterial activity of novel fluoroquinolone derivatives containing substituted piperidines |
| Q52605635 | Synthesis and in vitro antimicrobial activity screening of new pipemidic acid derivatives. |
| Q51093257 | Synthesis, Characterization, and Anti-Inflammatory Activities of Methyl Salicylate Derivatives Bearing Piperazine Moiety. |
| Q33947205 | The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors |
| Q26752640 | The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity |
| Q38743289 | The Structure-Antimicrobial Activity Relationships of a Promising Class of the Compounds Containing the N-Arylpiperazine Scaffold. |
| Q40922943 | The application of the micronucleus test in Chinese hamster V79 cells to detect drug-induced photogenotoxicity. |
| Q40636919 | The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? |
| Q34143393 | The fluoroquinolone antibacterials: past, present and future perspectives |
| Q35733987 | The fluoroquinolones: how long will their utility last? |
| Q33770053 | The future of the quinolones |
| Q34114448 | The new antibiotics |
| Q35649595 | The new fluoroquinolones: A critical review |
| Q36155438 | The quinolones: past, present, and future |
| Q40939756 | The role of new quinolones in the treatment of respiratory tract infections |
| Q34005865 | The safety profile of the fluoroquinolones. |
| Q40964316 | Tolerability of fluoroquinolone antibiotics. Past, present and future |
| Q33770084 | Toxicity of quinolones |
| Q37879173 | Trovafloxacin: a new fluoroquinolone |
| Q36729126 | Tuberculosis chemotherapy: recent developments and future perspectives |
| Q40758206 | Two fluoroquinolones and their combinations with hyaluronan: comparison of effects on canine chondrocyte culture |
| Q47101582 | Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities. |
| Q36088500 | Unveiling the Mode of Action of Two Antibacterial Tanshinone Derivatives |
| Q35216989 | Value of preapproval safety data in predicting postapproval hepatic safety and assessing the legitimacy of class warning |
| Q38502981 | Weighing the adverse cardiac effects of fluoroquinolones: A risk perspective |
| Q53931267 | [Quinolones]. |
Search more.